saridegib saridegib saridegib, also known as ipi-926, is an experimental drug candidate undergoing clinical trials for the treatment of various types of cancer, including hard-to-treat hematologic malignancies such as myelofibrosis and ligand-dependent tumors such as chondrosarcoma. ipi-926 exhibits its pharmacological effect by inhibition of the g protein-coupled receptor smoothened, a component of the hedgehog signaling pathway. chemically, it is a semi-synthetic derivative of the alkaloid cyclopamine. the process begins with cyclopamine extracted from harvested veratrum californicum which is taken through a series of alterations resulting in an analogue of the natural product cyclopamine, making ipi-926 the only compound in development/testing that is not fully synthetic. saridegib names iupac name n-methanesulfonamide systematic iupac name n-pyridine-2,9′-naphthoazulen]-3′-yl]methanesulfonamide other names saridegib identifiers cas number 1037210-93-7 y 3d model (jsmol) interactive image chembl chembl538867 chemspider 26353073 iuphar/bps 8198 kegg d10324 pubchem cid 25027363 unii jt96fpu35x y comptox dashboard (epa) dtxsid40146032 inchi inchi=1s/c29h48n2o3s/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31h,6-16h2,1-5h3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1key: hzlffncltrvyjg-wwgojcoqsa-n smiles c1c2((3(o2)cc45cc6c(cc6(5cc4=c(c3)c)c)ns(=o)(=o)c)c)nc1 properties chemical formula c29h48n2o3s molar mass 504.77 g·mol−1 pharmacology routes ofadministration oral legal status investigational except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). y verify (what is yn ?) infobox references saridegib is a member of a class of anti-cancer compounds known as hedgehog pathway inhibitors.